БУЛЛЕНС, Шерри (US),БАНТИНГ, Стюарт (US),ЧОУ, Тяньвэй (US),ОКХАМАФЕ, Аугустус, О. (US),ПРАЙС, Кристофер, П. (DE),ВЕНДТ, Дэниел, Дж. (US),ЯП, Кларенс (US)
申请号：
RU2020123892
公开号：
RU2020123892A
申请日:
2016.08.01
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
Disclosure Inner holds the purposes for providing c-type natriuretic peptide (CNP) variant, and novel pharmaceutical composition and preparation comprising CNP variant peptides, for treating, skeleton development is bad, for example long bone uptake of the undesirable one or more symptoms of skeleton development or the speed of growth and other has and skeleton development is bad and/or the lesion of the relevant symptoms of CNP or composition.
